ACM
TRVI icon

Aster Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Aster Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.78K Buy
+417
New +$6.07K ﹤0.01% 691
2026
Q1 		– Sell
-602
Closed -$7.54K – 1330
2025
Q4 		$7.54K Buy
+602
New +$6.96K ﹤0.01% 798

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Aster Capital Management's TRVI Position: Q2 2026 in Review

Aster Capital Management opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 417 shares worth $7.78K. The stake represents ﹤0.01% of the portfolio and ranks #691 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in TRVI as recently as Q4 2025.

Aster Capital Management first reported a position in TRVI in Q4 2025 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Aster Capital Management held 417 shares of Trevi Therapeutics worth $7.78K as of Q2 2026.
  • Trevi Therapeutics was a new Aster Capital Management position in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #691 holding.
  • Aster Capital Management first reported a position in Trevi Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.